Drug intelligence / Profile preview

orelabrutinib + obinutuzumab + lenalidomide

Development stage: Preclinical
Lead developer: InnoCare Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of orelabrutinib (a BTK inhibitor), obinutuzumab (an anti-CD20 monoclonal antibody), and lenalidomide (an immunomodulatory drug). While the obinutuzumab + lenalidomide combination (sometimes called GALEN) has been extensively studied for various lymphomas, particularly follicular lymphoma, the addition of orelabrutinib to this combination represents a potential novel approach that would combine three different mechanisms of action.

Targets

CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on orelabrutinib + obinutuzumab + lenalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on orelabrutinib + obinutuzumab + lenalidomide.

Explore the full profile